Home Newsfeeds Jefferies Downgrades Twilio to Hold, Lowers Price Target to $50

Jefferies Downgrades Twilio to Hold, Lowers Price Target to $50

Jefferies analyst Samad Samana downgrades Twilio (NYSE:TWLO) from Buy to Hold and lowers the price target from $110 to $50.

byBenzinga Newsdesk

November 28, 2022

1 minute read

Jefferies analyst Samad Samana downgrades Twilio (NYSE:TWLO) from Buy to Hold and lowers the price target from $110 to $50.

Why InMode Stock Is Plunging Today

By Vandana Singh

May 2, 10:42 AM

InMode Ltd (NASDAQ: INMD) sock is plunging today after the company reported a Q1 earnings beat, but the annual outlook lagged expectations.

INMD

EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer’s Immunotherapy Vaccine

By Vandana Singh

April 3, 7:34 AM

Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type.

ALZN

XPO Logistics Q2 EPS $1.81 Beats $1.51 Estimate, Sales $4.30B Beat $3.19B Estimate

By Benzinga Newsdesk

August 4, 4:32 PM

XPO Logistics (NYSE:XPO) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.51 by 19.87 percent. This is a 2.69 percent decrease over earnings of $1.86 per share from the same

XPO

GordonMD Invests In $150M Private Placement For Taysha Gene Therapies

By Happy Mohamed

August 21, 11:30 AM

GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused

TSHA

Jefferies Downgrades Twilio to Hold, Lowers Price Target to $50

Related Posts

Why InMode Stock Is Plunging Today

EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer’s Immunotherapy Vaccine

XPO Logistics Q2 EPS $1.81 Beats $1.51 Estimate, Sales $4.30B Beat $3.19B Estimate

GordonMD Invests In $150M Private Placement For Taysha Gene Therapies